# Cognex Corp: financial statements, quarterly

CGNX · Nasdaq · CIK 851205 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cgnx.md) · [Financials](/companies/cgnx/financials.md) · [Filings](/companies/cgnx/filings.md) · [Insiders](/companies/cgnx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cgnx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [197](/filings/0000851205-24-000079.md) | [197 d](/filings/0000851205-26-000012.md) | [211](/filings/0000851205-25-000031.md) | [239](/filings/0000851205-25-000052.md) | [235](/filings/0000851205-25-000064.md) | [230 d](/filings/0000851205-26-000012.md) | [216](/filings/0000851205-26-000040.md) | [249](/filings/0000851205-26-000065.md) | [277](/filings/0000851205-25-000064.md) | [252 d](/filings/0000851205-26-000012.md) | [268](/filings/0000851205-26-000040.md) | [291](/filings/0000851205-26-000065.md) |
| Cost of revenue | $m | [54.5](/filings/0000851205-24-000079.md) | [61.6 d](/filings/0000851205-26-000012.md) | [68.9](/filings/0000851205-25-000031.md) | [72.7](/filings/0000851205-25-000052.md) | [75.3](/filings/0000851205-25-000064.md) | [71.8 d](/filings/0000851205-26-000012.md) | [71.7](/filings/0000851205-26-000040.md) | [81.2](/filings/0000851205-26-000065.md) | [89.6](/filings/0000851205-25-000064.md) | [86.4 d](/filings/0000851205-26-000012.md) | [77.5](/filings/0000851205-26-000040.md) | [85.5](/filings/0000851205-26-000065.md) |
| Gross profit | $m | [143](/filings/0000851205-24-000079.md) | [135 d](/filings/0000851205-26-000012.md) | [142](/filings/0000851205-25-000031.md) | [167](/filings/0000851205-25-000052.md) | [159](/filings/0000851205-25-000064.md) | [158 d](/filings/0000851205-26-000012.md) | [144](/filings/0000851205-26-000040.md) | [168](/filings/0000851205-26-000065.md) | [187](/filings/0000851205-25-000064.md) | [166 d](/filings/0000851205-26-000012.md) | [191](/filings/0000851205-26-000040.md) | [206](/filings/0000851205-26-000065.md) |
| Research and development | $m | [32.6](/filings/0000851205-24-000079.md) | [34.7 d](/filings/0000851205-26-000012.md) | [37.1](/filings/0000851205-25-000031.md) | [35.0](/filings/0000851205-25-000052.md) | [35.2](/filings/0000851205-25-000064.md) | [32.5 d](/filings/0000851205-26-000012.md) | [34.7](/filings/0000851205-26-000040.md) | [33.1](/filings/0000851205-26-000065.md) | [35.1](/filings/0000851205-25-000064.md) | [36.1 d](/filings/0000851205-26-000012.md) | [37.0](/filings/0000851205-26-000040.md) | [32.4](/filings/0000851205-26-000065.md) |
| Selling, general and administrative | $m | [82.3](/filings/0000851205-24-000079.md) | [90.4 d](/filings/0000851205-26-000012.md) | [90.6](/filings/0000851205-25-000031.md) | [93.2](/filings/0000851205-25-000052.md) | [92.6](/filings/0000851205-25-000064.md) | [94.5 d](/filings/0000851205-26-000012.md) | [83.5](/filings/0000851205-26-000040.md) | [91.3](/filings/0000851205-26-000065.md) | [94.4](/filings/0000851205-25-000064.md) | [94.6 d](/filings/0000851205-26-000012.md) | [94.0](/filings/0000851205-26-000040.md) | [87.9](/filings/0000851205-26-000065.md) |
| Operating income | $m | [30.6](/filings/0000851205-24-000079.md) | [12.7 d](/filings/0000851205-26-000012.md) | [14.2](/filings/0000851205-25-000031.md) | [38.5](/filings/0000851205-25-000052.md) | [31.6](/filings/0000851205-25-000064.md) | [30.8 d](/filings/0000851205-26-000012.md) | [26.1](/filings/0000851205-26-000040.md) | [43.4](/filings/0000851205-26-000065.md) | [57.8](/filings/0000851205-25-000064.md) | [35.3 d](/filings/0000851205-26-000012.md) | [59.9](/filings/0000851205-26-000040.md) | [85.5](/filings/0000851205-26-000065.md) |
| Income tax | $m | [8.1](/filings/0000851205-24-000079.md) | [3.1 d](/filings/0000851205-26-000012.md) | [5.5](/filings/0000851205-25-000031.md) | [5.4](/filings/0000851205-25-000052.md) | [7.0](/filings/0000851205-25-000064.md) | [7.5 d](/filings/0000851205-26-000012.md) | [4.2](/filings/0000851205-26-000040.md) | [7.6](/filings/0000851205-26-000065.md) | [45.2](/filings/0000851205-25-000064.md) | [11.4 d](/filings/0000851205-26-000012.md) | [10.1](/filings/0000851205-26-000040.md) | [16.5](/filings/0000851205-26-000065.md) |
| Net income | $m | [18.9](/filings/0000851205-24-000079.md) | [11.2 d](/filings/0000851205-26-000012.md) | [12.0](/filings/0000851205-25-000031.md) | [36.2](/filings/0000851205-25-000052.md) | [29.6](/filings/0000851205-25-000064.md) | [28.3 d](/filings/0000851205-26-000012.md) | [23.6](/filings/0000851205-26-000040.md) | [40.5](/filings/0000851205-26-000065.md) | [17.7](/filings/0000851205-25-000064.md) | [32.7 d](/filings/0000851205-26-000012.md) | [51.7](/filings/0000851205-26-000040.md) | [72.8](/filings/0000851205-26-000065.md) |
| Diluted EPS | $ per share | [0.11](/filings/0000851205-24-000079.md) | not reported | [0.07](/filings/0000851205-25-000031.md) | [0.21](/filings/0000851205-25-000052.md) | [0.17](/filings/0000851205-25-000064.md) | not reported | [0.14](/filings/0000851205-26-000040.md) | [0.24](/filings/0000851205-26-000065.md) | [0.10](/filings/0000851205-25-000064.md) | not reported | [0.31](/filings/0000851205-26-000040.md) | [0.43](/filings/0000851205-26-000065.md) |
| Basic EPS | $ per share | [0.11](/filings/0000851205-24-000079.md) | not reported | [0.07](/filings/0000851205-25-000031.md) | [0.21](/filings/0000851205-25-000052.md) | [0.17](/filings/0000851205-25-000064.md) | not reported | [0.14](/filings/0000851205-26-000040.md) | [0.24](/filings/0000851205-26-000065.md) | [0.11](/filings/0000851205-25-000064.md) | not reported | [0.31](/filings/0000851205-26-000040.md) | [0.43](/filings/0000851205-26-000065.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-01) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [396](/filings/0000851205-23-000020.md) | [203](/filings/0000851205-25-000012.md) | [139](/filings/0000851205-24-000051.md) | [177](/filings/0000851205-24-000071.md) | [197](/filings/0000851205-24-000079.md) | [186](/filings/0000851205-26-000012.md) | [144](/filings/0000851205-25-000031.md) | [179](/filings/0000851205-25-000052.md) | [246](/filings/0000851205-25-000064.md) | [263](/filings/0000851205-26-000065.md) | [237](/filings/0000851205-26-000040.md) | [303](/filings/0000851205-26-000065.md) |
| Current assets | $m | [847](/filings/0000851205-23-000020.md) | [679](/filings/0000851205-25-000012.md) | [662](/filings/0000851205-24-000051.md) | [681](/filings/0000851205-24-000071.md) | [672](/filings/0000851205-24-000079.md) | [613](/filings/0000851205-26-000012.md) | [578](/filings/0000851205-25-000031.md) | [626](/filings/0000851205-25-000052.md) | [671](/filings/0000851205-25-000064.md) | [697](/filings/0000851205-26-000065.md) | [690](/filings/0000851205-26-000040.md) | [850](/filings/0000851205-26-000065.md) |
| Total assets | $m | [1,990](/filings/0000851205-23-000020.md) | [2,018](/filings/0000851205-25-000012.md) | [2,013](/filings/0000851205-24-000051.md) | [2,004](/filings/0000851205-24-000071.md) | [2,063](/filings/0000851205-24-000079.md) | [1,993](/filings/0000851205-26-000012.md) | [1,933](/filings/0000851205-25-000031.md) | [2,004](/filings/0000851205-25-000052.md) | [2,003](/filings/0000851205-25-000064.md) | [2,017](/filings/0000851205-26-000065.md) | [2,006](/filings/0000851205-26-000040.md) | [2,179](/filings/0000851205-26-000065.md) |
| Current liabilities | $m | [170](/filings/0000851205-23-000020.md) | [152](/filings/0000851205-25-000012.md) | [188](/filings/0000851205-24-000051.md) | [169](/filings/0000851205-24-000071.md) | [171](/filings/0000851205-24-000079.md) | [169](/filings/0000851205-26-000012.md) | [184](/filings/0000851205-25-000031.md) | [190](/filings/0000851205-25-000052.md) | [169](/filings/0000851205-25-000064.md) | [184](/filings/0000851205-26-000065.md) | [189](/filings/0000851205-26-000040.md) | [216](/filings/0000851205-26-000065.md) |
| Total liabilities | $m | [501](/filings/0000851205-23-000020.md) | [513](/filings/0000851205-25-000012.md) | [524](/filings/0000851205-24-000051.md) | [497](/filings/0000851205-24-000071.md) | [496](/filings/0000851205-24-000079.md) | [475](/filings/0000851205-26-000012.md) | [487](/filings/0000851205-25-000031.md) | [497](/filings/0000851205-25-000052.md) | [513](/filings/0000851205-25-000064.md) | [525](/filings/0000851205-26-000065.md) | [527](/filings/0000851205-26-000040.md) | [549](/filings/0000851205-26-000065.md) |
| Shareholders' equity | $m | [1,489](/filings/0000851205-24-000079.md) | [1,505](/filings/0000851205-26-000012.md) | [1,489](/filings/0000851205-25-000052.md) | [1,507](/filings/0000851205-25-000064.md) | [1,567](/filings/0000851205-25-000064.md) | [1,518](/filings/0000851205-26-000065.md) | [1,446](/filings/0000851205-26-000065.md) | [1,506](/filings/0000851205-26-000065.md) | [1,490](/filings/0000851205-25-000064.md) | [1,492](/filings/0000851205-26-000065.md) | [1,479](/filings/0000851205-26-000065.md) | [1,630](/filings/0000851205-26-000065.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [41.0 d](/filings/0000851205-24-000079.md) | [14.5 d](/filings/0000851205-26-000012.md) | [13.6](/filings/0000851205-25-000031.md) | [27.8 d](/filings/0000851205-25-000052.md) | [56.3 d](/filings/0000851205-25-000064.md) | [51.4 d](/filings/0000851205-26-000012.md) | [40.5](/filings/0000851205-26-000040.md) | [42.6 d](/filings/0000851205-26-000065.md) | [87.5 d](/filings/0000851205-25-000064.md) | [74.9 d](/filings/0000851205-26-000012.md) | [45.1](/filings/0000851205-26-000040.md) | [69.2 d](/filings/0000851205-26-000065.md) |
| Capital expenditure | $m | [5.9 d](/filings/0000851205-24-000079.md) | [7.0 d](/filings/0000851205-26-000012.md) | [4.1](/filings/0000851205-25-000031.md) | [4.5 d](/filings/0000851205-25-000052.md) | [4.4 d](/filings/0000851205-25-000064.md) | [2.1 d](/filings/0000851205-26-000012.md) | [2.5](/filings/0000851205-26-000040.md) | [2.2 d](/filings/0000851205-26-000065.md) | [1.5 d](/filings/0000851205-25-000064.md) | [2.6 d](/filings/0000851205-26-000012.md) | [2.8](/filings/0000851205-26-000040.md) | [1.5 d](/filings/0000851205-26-000065.md) |
| Dividends paid | $m | [12.0 d](/filings/0000851205-24-000079.md) | [12.9 d](/filings/0000851205-26-000012.md) | [12.9](/filings/0000851205-25-000031.md) | [12.9 d](/filings/0000851205-25-000052.md) | [12.9 d](/filings/0000851205-25-000064.md) | [13.7 d](/filings/0000851205-26-000012.md) | [13.6](/filings/0000851205-26-000040.md) | [13.4 d](/filings/0000851205-26-000065.md) | [13.4 d](/filings/0000851205-25-000064.md) | [14.2 d](/filings/0000851205-26-000012.md) | [14.2](/filings/0000851205-26-000040.md) | [14.3 d](/filings/0000851205-26-000065.md) |
| Share repurchases | $m | [10.5 d](/filings/0000851205-24-000079.md) | [20.2 d](/filings/0000851205-26-000012.md) | [9.3](/filings/0000851205-25-000031.md) | [10.5 d](/filings/0000851205-25-000052.md) | [4.0 d](/filings/0000851205-25-000064.md) | [43.2 d](/filings/0000851205-26-000012.md) | [102](/filings/0000851205-26-000040.md) | [0.0 d](/filings/0000851205-26-000065.md) | [24.0 d](/filings/0000851205-25-000064.md) | [25.0 d](/filings/0000851205-26-000012.md) | [99.0](/filings/0000851205-26-000040.md) | [6.2 d](/filings/0000851205-26-000065.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-02) | Q1 FY2023 (2023-04-02) | Q2 FY2023 (2023-07-02) | Q3 FY2023 (2023-10-01) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q1 FY2026 (2026-04-05) | Q2 FY2026 (2026-07-05) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [174](/filings/0000851205-23-000020.md) | [174](/filings/0000851205-24-000051.md) | [174](/filings/0000851205-24-000071.md) | [173](/filings/0000851205-24-000079.md) | [173](/filings/0000851205-25-000031.md) | [173](/filings/0000851205-25-000052.md) | [173](/filings/0000851205-25-000064.md) | [170](/filings/0000851205-26-000040.md) | [169](/filings/0000851205-26-000065.md) | [169](/filings/0000851205-25-000064.md) | [168](/filings/0000851205-26-000040.md) | [170](/filings/0000851205-26-000065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 168,223,842 at 2026-08-02, from the cover of the [10-Q filed 2026-08-06](/filings/0000851205-26-000065.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.